With the support of the wider Quest Diagnostics infrastructure, collaborate with our specialized oncology teams. They're adept at both therapeutic and diagnostic development, all centered around a key goal: ensuring patients can access your essential therapy.
Advancing breast cancer diagnostics, we join forces with pharma and diagnostic stakeholders. Harnessing next-generation biomarkers and personalized assessments, we're reshaping early detection, diagnosis, and monitoring strategies.
Navigating the intricacies of the digestive system, our comprehensive diagnostic offerings tackle both colorectal and gastrointestinal cancers. From genetic mutation assessments to metabolic pathway analyses, we work to provide clearer insights, guiding patients and clinicians towards informed therapeutic decisions.
Leukemias and lymphomas present unique diagnostic challenges. Through our exhaustive panels and state-of-the-art genetic testing, we aim to provide clarity in these intricate cases.
Timely identification is crucial in the fight against lung cancer. By integrating comprehensive genomic profiling with traditional pathology, we aim to provide a more detailed understanding, guiding tailored treatment approaches.
Championing improved patient outcomes, our diagnostic solutions cater to those grappling with pancreatic malignancies, aiding early detection and therapeutic guidance.
Our holistic suite offers a blend of early detection tests, risk stratification, and advanced molecular profiling, honing the management of prostate cancer patients.
Our robust portfolio, ranging from checkpoint inhibitor assessments to tumor mutational burden analyses, is curated to be a cornerstone in the realm of cancer immunotherapy.
Quest remains at the cutting edge of genomic medicine. Our offerings, from single-gene to whole exome sequencing, empower healthcare professionals with the tools to tackle complex malignancies.
Our mission is to elevate precision oncology. With our extensive molecular panels, we offer insights into a multitude of targetable mutations, laying the foundation for bespoke treatment regimens.
As a unique global R&D entity supporting preclinical discovery to diagnostic commercialization, our goal is to help you reach your milestones more efficiently. We prioritize seamless transitions, conserving insights and understanding as you progress through each phase.
Enhance your oncology strategy to resonate more meaningfully with the global community affected by cancer.
We ensure synchronicity between diagnostics and therapeutics from the get-go, optimizing both patient accessibility and your return on investment.
When it comes to the commercialization of a new pharmaceutical product, time is of the essence. We support Day 1 Ready Lab testing, education, awareness, and support programs to ensure patients can receive the therapy they need without delay.
Rely on Quest for a cohesive, end-to-end service experience. Our streamlined, integrated offering combines scientific expertise, customer service, information technology, specimen collection, transport teams, and high-quality testing, including:
• Specimen collection centers
• Mobile collection units
• Expert interpretation
With access to over 60 billion lab test results, an expanding range of more than 3,500 assays, and a database encompassing approximately half of the US population, we are poised to provide you with the insights necessary for data-informed decision-making at pivotal development junctures.
Tap into our vast commercialization know-how, bolstered by our versatile team. We present a rich portfolio alongside tailored partnership solutions:
This 523-gene test helps oncologists deliver precision medicine by providing personalized genomic analysis of a patient’s tumor. The expanded panel offers the opportunity for a broader scope of genomic information. For example, it may be useful for patients with limited or ill-defined treatment options and for those considering clinical trials. The addition of tumor mutation burden (TMB) and microsatellite instability (MSI) also enable simultaneous assessment of eligibility for immune checkpoint inhibitors. Tumor profiling with next-generation sequencing allows evaluation of many genomic biomarkers simultaneously.
Genes covered
523 (see complete list of genes included)
Analysis
cfDNA
Turnaround time
14 days after receipt of sample in the laboratory for prospective analysis
The escalating global challenge of oncology care demands new approaches to detection, diagnosis, and treatment.
Dive into the transformative world of healthcare with "Pathology in the era of precision medicine," a whitepaper that brings to light the evolving role of pathology in the age of personalized treatment.
Contact our pharma solutions experts to design a custom program to accommodate the needs of your study.
Connect with our team of experts today.
The evolving role of diagnostic labs in oncology: navigating biomarker-driven therapies
Learn more
Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services. Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services.
Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.
